Minimally invasive bronchitis therapy gets CE marking

Gala Therapeutics announced that its RheOx system has received CE mark in the European Union.

In a minimally invasive procedure called bronchial rheoplasty, RheOx delivers non-thermal energy to the airways to reduce mucous-producing cells in patients with chronic bronchitis.

RheOx is a bronchoscopic system designed to reduce mucous-producing cells in patients with chronic bronchitis. The revolutionary technology includes an electrosurgical generator and a single-use catheter that together deliver non-thermal energy to the airways to reduce the number of abnormal mucous-producing cells in the lungs, making way for new normal
cells to redevelop.

Gala plans to launch a post-market study at key European respiratory centres of excellence.